title: Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.
authors.affiliation: Corporació Sanitaria Parc Tauli, Sabadell, Spain. esaigi@cspt.es
authors.forename: Eugeni
authors.initials: E
authors.lastname: Saigi
authors.forename: Antonieta
authors.initials: A
authors.lastname: Salut
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Campos
authors.forename: Ferran
authors.initials: F
authors.lastname: Losa
authors.forename: Hermini
authors.initials: H
authors.lastname: Manzano
authors.forename: Eduard
authors.initials: E
authors.lastname: Batiste-Alentorn
authors.forename: Angels
authors.initials: A
authors.lastname: Acusa
authors.forename: Edelmira
authors.initials: E
authors.lastname: Vélez de Mendizabal
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Guasch
authors.forename: Isabel
authors.initials: I
authors.lastname: Antón
mesh_terms: D000328:Adult; D000368:Aged; D002166:Camptothecin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016001:Confidence Intervals; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
chemical_list: D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin